Fig. 1

Liraglutide biosimilar Phase III Study flow diagram. HbA1c% (rhombus) was measured at baseline (screening), week 12, week 18 and week 24. Source: Supplementary material, Phase III trial of Liraglutide Biosimilar, Diabetes Research and Clinical Practice, Volume 207, 111,034